Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Ginkgo Bioworks

Ginkgo Bioworks

Ginkgo Bioworks is a synthetic biology and biotechnology company using machine learning techniques and lab automation to engineer microorganisms as a service.

All edits

Edits on 7 Dec, 2022
Amy Tomlinson Gayle
Amy Tomlinson Gayle edited on 7 Dec, 2022
Edits made to:
Timeline (+8/-1 characters)
Article (+91/-79 characters)
Article

Ginkgo Bioworks, based in Boston, Massachusetts, is a synthetic biology and biotechnology company that specializes in creating various microbes through the practice of genetic engineering. Ginkgo Bioworks was founded in 2008 by Jason Kelly, Reshma Shetty, Barry Canton, Austin Che, and Tom Knight. Ginkgo was described by Jason Kelly as a science and engineering platform that other companies use to develop biomanufactured products. Ginkgo plans to make profits by taking royalties or shares of theirits customers’ revenues.

...

Ginkgo Bioworks designs microbes in analytical labs called biofoundries, which are comprised of software and hardware tools that allow for rapid prototyping and high-throughput screening. As of 2022, Ginkgo Bioworks has four biofoundries (Bioworks1 through Bioworks4), where it pursues various projects such as fragrances, flavors, probiotics, and more. The company works with customers to develop custom microbes for such purposes.

...

Ginkgo Bioworks uses Python code to pull out DNA sequences that might produce a gene to make a desired product, like a specific fragrance. Robots are used to print out and assemble the DNA sequences and insert them into bacteria or yeast. The bacteria and yeast strains are tested for fitness, efficiency, and yield. Data from this process are captured and used to build design principles to make the future engineering of organisms more efficient. With automated robots, one Ginkgo operator can perform around 1,000 DNA extractions in a day.

...

Ginkgo helped Aldevron improve the production of capping enzymes, a component of mRNA vaccines.

...

In June 2016, Ginkgo Bioworks and Amyris entered into an Initialinitial Strategicstrategic Partnershippartnership Agreementagreement to accelerate the commercialization of various bio-based ingredients, partly by allowing Amyris to access Ginkgo Bioworks's first biofoundry. The partnership agreement was confirmed in September 2016.

...

In September 2018, Ginkgo Bioworks partnered with Cronos Group, a cannabis company, to produce a line of cultured, concentrated cannabinoids with individual properties targetting different medical concerns––chronic pain, nausea, nervous disorders, and more. In August 2021, the two companies announced they had achieved their first target productivity milestone for cannabigerolic acid (CBGA), which moved them closer towardsto thiertheir goal of producing eight cultured cannabinoids. The cannabis company Cronos produces a THC and CBG infusedCBG-infused gummy cannabis edible in which the cannabigerol (CBG) is produced in yeast.

...

Genomatica and Ginkgo Bioworks announced an alliance on September 29, 2016, to rapidly deliver biology-based solutions for various high-volume chemicals. The alliance is designed to help transition industries away from mainstream chemicals and switch them to biological process technology, which can be more economical, and sustainable, and give a better product performance.

...

In June 2021, Ginkgo Bioworks partnered with Sumitomo Chemical, one of the world's largest agrochemical producers. The partnership aims to increase the production efficiency and sustainability of a bio-based commercial product and to replace petroleum-based products.

...

On December 8, 2017, Ginkgo Bioworks and Synlogic announced a collaboration to create new living medicines for neurological and liver disorders. In November 2021, the first investigational medicine developed on Ginkgo's platform to enter IND-enabling studies was the Synthetic BioticTM medicine called SYNB1353, an engineered strain of E. coli Nissle (EcN) designed to treat homocystinuria. Homocystinuria is an inherited disorder in which the body cannot metabolize methionine. IND-enabling studies include preclinical pharmacology, toxicology, metabolism, and manufacturing studies that allow for the submission of a formal application with the FDA or EMA of an investigational new drug (IND).

...

Motif Ingredients, which spun out of Ginkgo Bioworks in February 2019, creates synthetic proteins that provide the various flavors and textures of animal products like beef and dairy to be used in plant-based food products. Motif produces Hemami, a yeast-derived heme protein whichthat adds the umami flavor and smell of meats to plant-based meat alternative foods. The plant-based food company Impossible Foods sued Motif in March, 2022, claiming infringement of patents related to imitation meat that uses the protein heme.

...

0Company -1Patents

Patent description
Inventor
Status
Date
App/pub number

Joseph Jacobson

Application

2018-02-01

WO2018022972A1

Patrick Boyle, Reshma P. Shetty

Application

2015-10-01

WO2015148680A1

Jeffrey C. Way, Joseph H. Davis

Application

2012-03-22

US20120070870A1

Reshma Shetty, Thomas F. Knight Jr., Randall D. Rettberg

Grant

2016-11-29

US9506167B2

Curt R. Fischer, Austin J. Che, Reshma P. Shetty, Jason R. Kelly

Grant

2013-01-08

US8349587B2

Timeline

October 6, 2021

Scorpion Capital, a short seller, publishes a report claiming that Ginkgo Bioworks is a "shell game" and "colossal scam," resulting in an immediate 20% percent drop in share value.
Edits on 6 Dec, 2022
Meredith Hanel
Meredith Hanel edited on 6 Dec, 2022
Edits made to:
Article (+774 characters)
Article
Aldevron

Ginkgo helped Aldevron improve production of capping enzymes, a component of mRNA vaccines.

...

In September 2018, Ginkgo Bioworks partnered with Cronos Group, a cannabis company, to produce a line of cultured, concentrated cannabinoids with individual properties targetting different medical concerns––chronic pain, nausea, nervous disorders, and more. In August 2021, the two companies announced they had achieved their first target productivity milestone for cannabigerolic acid (CBGA), which moved them closer towards thier goal of producing eight cultured cannabinoids. The cannabis company Cronos produces a THC and CBG infused gummy cannabis edible in which the cannabigerol (CBG) is produced in yeast.

...
Robertet

Flavor and additives company Robertet produces the fragrance molecule gamma-decalactone and the flavoring substance massoia lactone with yeast engineered by Ginkgo. Massoia lactone is normally isolated from the bark of a tropical tree.

...

Motif Ingredients, which spun out of Ginkgo Bioworks in February 2019, creates synthetic proteins that provide the various flavors and textures of animal products like beef and dairy to be used in plant-based food products. Motif produces Hemami, a yeast-derived heme protein which adds the umami flavor and smell of meats to plant-based meat alternative foods. The plant-based food company Impossible Foods sued Motif in March, 2022 claiming infringement of patents related to imitation meat that uses the protein heme.

Meredith Hanel
Meredith Hanel edited on 6 Dec, 2022
Edits made to:
Timeline (-1 events) (-171 characters)
Article (+287/-378 characters)
Article

Ginkgo Bioworks, based in Boston, Massachusetts, is a synthetic biology and biotechnology company that specializes in creating various microbes through the practice of genetic engineering. Ginkgo Bioworks was founded in 2008 by Jason Kelly, Reshma Shetty, Barry Canton, Austin Che, and Tom Knight. Ginkgo was described by Jason Kelly as a science and engineering platform that other companies use to develop biomanufactured products. Ginkgo plans to make profits by taking royalties or shares of their customers’ revenues.

...

On December 8, 2017, Ginkgo Bioworks and Synlogic announced a collaboration to create new living medicines for neurological and liver disorders. In November 2021, first investigational medicine developed on Ginkgo's platform to enter IND-enabling studies was the Synthetic BioticTM medicine called SYNB1353, an engineered strain of E. coli Nissle (EcN) designed to treat homocystinuria. Homocystinuria is an inherited disorder in which the body cannot metabolize methionine. IND-enabling studies include preclinical pharmacology, toxicology, metabolism and manufacturing studies that allow for the submission of a formal application with the FDA or EMA of an investigational new drug (IND).

...

Ginkgo Bioworks CEO Jason Kelly said of acquiring Gen9:

Our mission is to make biology easier to engineer and through that to enable our customers to grow better products. Having Gen9’s synthesis and assembly technology available to our customers is a valuable addition to our foundries, allowing us to further speed up the process of organism design.
...

Ginkgo Bioworks acquired Novogy in December 2020 and integrated its codebase and team expertise into Ginkgo's own bioengineering platform. A majority of Novogy's technical team joined Ginkgo Bioworks in the acquisition. With Novogy's lipid-producing yeast strains, Ginkgo Bioworks has been able to accelerateaccelerated its development of bio-based oils, which can be utilized to make more eco-friendly products.

...

Motif Ingredients, which spun out of Ginkgo Bioworks in February 2019, creates synthetic proteins that provide the various flavors and textures of animal products like beef and dairy to be used in plant-based food products.

Timeline

April 22, 2022

Ginkgo Bioworks announces plans to expand its platform capabilities in agricultural biologicals by acquiring Bayer's West Sacramento Biologics Research & Development site.
Meredith Hanel
Meredith Hanel edited on 6 Dec, 2022
Edits made to:
Description (+22 characters)
Article (+552/-33 characters)
Topic thumbnail

Ginkgo Bioworks

Ginkgo Bioworks is a synthetic biology and biotechnology company using machine learning techniques and lab automation to engineer microorganisms as a service.

Article

Ginkgo Bioworks, based in Boston, Massachusetts, is a synthetic biology and biotechnology company that specializes in creating various microbes through the practice of genetic engineering. Ginkgo Bioworks was founded in 2008 by Jason Kelly, Reshma Shetty, Barry Canton, Austin Che, and Tom Knight.

...

Ginkgo Bioworks designs microbes in analytical labs called biofoundries, which are comprised of software and hardware tools that allow for rapid prototyping and high-throughput screening. As of 2022, Ginkgo Bioworks has four biofoundries (Bioworks1 through Bioworks4) where it pursues various projects such as fragrances, flavors, probiotics, and more. The company works with customers to develop custom microbes for such purposes.

...

In September 2018, Ginkgo Bioworks partnered with Cronos Group, a cannabis company, to produce a line of cultured, concentrated cannabinoids with individual properties targetting different medical concerns––chronic pain, nausea, nervous disorders, and more. In August 2021, the two companies announced they had achieved their first target productivity milestone for cannabigerolic acid (CBGA), which moved them closer towards thier goal of producing eight cultured cannabinoids.

...

On December 8, 2017, Ginkgo Bioworks and Synlogic announced a collaboration to create new living medicines for neurological and liver disorders. In November 2021, the first investigational medicine developed on Ginkgo's platform to enter IND-enabling studies was developed: an investigationalthe Synthetic BioticTM medicine called SYNB1353, designed to treat homocystinuria. Homocystinuria is an inherited disorder in which the body cannot metabolize methionine. IND-enabling studies include preclinical pharmacology, toxicology, metabolism and manufacturing studies that allow for the submission of a formal application with the FDA or EMA of an investigational new drug (IND).

AbdulRiots
AbdulRiots edited on 6 Dec, 2022
Edits made to:
Infobox (+2/-1 properties)
Infobox
Also Known As
Primus
Funding Type
Edits on 21 Nov, 2022
Megan Gustafson
Megan Gustafson edited on 21 Nov, 2022
Edits made to:
Timeline (+1/-1 events) (+162/-88 characters)
Timeline

October 18, 2022

Ginkgo Expands Agricultural Biologicals Division, Closes Deal with Bayer Ginkgo Bioworks

October 18, 2022

Ginkgo acquires Bayer’s West Sacramento Biologics Research & Development site and platform, and they are integrated into Ginkgo’s agricultural biologics division.
Edits on 20 Nov, 2022
Nguyen Trang Anh
Nguyen Trang Anh edited on 20 Nov, 2022
Infobox
Board of Directors
Nguyen Trang Anh"Senior vice president of biopharma manufacturing and life sciences tools"
Nguyen Trang Anh edited on 20 Nov, 2022
Edits made to:
Infobox (+1 properties)
Infobox
Board of Directors
Nguyen Trang Anh
Nguyen Trang Anh edited on 20 Nov, 2022
Edits made to:
Timeline (+1 events) (+88 characters)
Timeline

October 18, 2022

Ginkgo Expands Agricultural Biologicals Division, Closes Deal with Bayer Ginkgo Bioworks
Edits on 18 Nov, 2022
Benjamin Metcalfe
Benjamin Metcalfe edited on 18 Nov, 2022
Infobox
Company Operating Status
Active
Edits on 10 Nov, 2022
Jen English
Jen English edited on 10 Nov, 2022
Edits made to:
Infobox (+2/-1 properties)
Infobox
Is a
Edits on 1 Nov, 2022
Megan Gustafson"Restore LinkedIn"
Megan Gustafson edited on 1 Nov, 2022
Edits made to:
Infobox (+1 properties)
Infobox
Golden AI"Infobox creation from: Wikidata data enrichment"
Golden AI approved a suggestion from Golden's AI on 1 Nov, 2022
Edits made to:
Infobox (+1 properties)
Infobox
Location
Murmur Murmur
Murmur Murmur edited on 1 Nov, 2022
Edits made to:
Infobox (-2 properties)
Infobox
Coiner Elle
Coiner Elle edited on 1 Nov, 2022
Edits made to:
Infobox (-4 properties)
Infobox
Public Enemy
Public Enemy edited on 1 Nov, 2022
Infobox
Accelerator
Accelerator Batch
Investors
Edits on 31 Oct, 2022
Megan Gustafson"Inaccurate "
Megan Gustafson edited on 31 Oct, 2022
Edits made to:
Infobox (-9 properties)
Infobox
Acquisition Transaction
Fax Number
1
First Release
April 4, 2019
Funding Round Investor
Latest Release
May 28, 2020
Edits on 30 Oct, 2022
pandu satria pamungkas
pandu satria pamungkas edited on 30 Oct, 2022
Edits made to:
Infobox (+9 properties)
Infobox
Acquisition Transaction
Fax Number
1
First Release
April 4, 2019
Funding Round Investor
Latest Release
May 28, 2020
Edits on 28 Oct, 2022
pandu satria pamungkas
pandu satria pamungkas edited on 28 Oct, 2022
Edits made to:
Infobox (+3 properties)
Infobox
pandu satria pamungkas
pandu satria pamungkas edited on 28 Oct, 2022
Golden logo
By using this site, you agree to our Terms & Conditions.